Abstract: The present disclosure relates to methods and compositions that allow one to identify in vivo edited cells when employing nucleic-acid guided editing. Additionally provided are automated multi-module instruments for performing editing and selection methods and using the compositions.
Type:
Grant
Filed:
February 24, 2022
Date of Patent:
June 14, 2022
Assignee:
Inscripta, Inc.
Inventors:
Aamir Mir, Andrew Garst, Stephen Federowicz, Kyle Seamon
Abstract: The present disclosure provides new RNA-guided nucleases for making rational, direct edits to nucleic acids in live cells; specifically, the present disclosure provides Type V MAD nucleases (e.g., RNA-guided nucleases or RGNs) with altered PAM preferences and/or altered activity at different temperatures or fidelity, and/or varied nuclease activities; all changes that may increase the versatility of a nucleic acid-guided nuclease for certain editing tasks.
Abstract: The present disclosure provides shuttle vectors for editing exogenous polynucleotides in heterologous live cells, as well as automated methods, modules, and multi-module cell editing instruments and systems for performing the editing methods.
Abstract: The present disclosure relates to methods for increasing observed editing rates in the surviving bacteria cells. The compositions and methods presented herein in combination lead to a phenomenon of “edit or die.” Although less cells survive plating and editing, a large percentage of cells that do survive are multiple editors. In one experiment it was found that if a cell survives transformation, plating, and editing, 75% of the surviving cells are multiple editors; that is, 75% of the surviving cells were simultaneously edited with edits at two or more different locations within the bacterial genome.
Type:
Grant
Filed:
November 28, 2021
Date of Patent:
May 3, 2022
Assignee:
Inscripta, Inc.
Inventors:
Tian Tian, Eileen Spindler, Charles Johnson, Clint Davis
Abstract: The present disclosure provides new RNA-guided nuclease systems and engineered nickases for making rational, direct edits to nucleic acids in live cells.
Abstract: Disclosed herein are nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Disclosed herein are engineered non-naturally occurring nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Targetable nuclease systems can be used to edit genetic targets, including recursive genetic engineering and trackable genetic engineering methods.
Type:
Grant
Filed:
December 17, 2021
Date of Patent:
April 19, 2022
Assignee:
Inscripta, Inc.
Inventors:
Andrew Garst, Ryan T. Gill, Tanya Elizabeth Warnecke Lipscomb
Abstract: The present disclosure relates to compositions, methods, modules and automated integrated instrumentation for multiplex delivery of “landing pad” edits into the genomes of a population of live cells. The landing pads then may be leveraged to insert very large DNA sequences into the genomes of the population of live cells.
Abstract: The present disclosure provides instrumentation and automated methods for creating cell surface display libraries, where the cells of the library display engineered peptides on their cell surfaces for identification of antigens that bind to T-cell receptors. The engineered peptides may be putative antigens or binding regions of the T-cell receptors.
Type:
Grant
Filed:
September 10, 2020
Date of Patent:
April 5, 2022
Assignee:
Inscripta, Inc.
Inventors:
Stephen Federowicz, Deanna Church, Michael Graige
Abstract: In an illustrative embodiment, automated multi-module cell editing instruments are provided to automate multiple edits into nucleic acid sequences inside one or more cells.
Type:
Grant
Filed:
November 30, 2021
Date of Patent:
April 5, 2022
Assignee:
Inscripta, Inc.
Inventors:
Jorge Bernate, Kevin Ness, Phillip Belgrader, Don Masquelier, Ryan Gill
Abstract: The present disclosure relates to methods and compositions that allow one to identify in vivo edited cells when employing nucleic-acid guided editing. Additionally provided are automated multi-module instruments for performing editing and selection methods and using the compositions.
Type:
Grant
Filed:
November 15, 2021
Date of Patent:
March 29, 2022
Assignee:
Inscripta, Inc.
Inventors:
Aamir Mir, Andrew Garst, Stephen Federowicz, Kyle Seamon
Abstract: This invention relates to compositions of matter, methods, modules and instruments for automated mammalian cell growth and mammalian cell transduction followed by nucleic acid-guided nuclease editing in live mammalian cells. The present compositions and methods entail viral delivery of an editing cassette to live mammalian cells such that the editing cassettes edit the cells and the edited cells continue to grow, preferably using a fully-automated end-to-end instrument to process the cells without human intervention to enhance cell processing uniformity and to maintain the integrity of the cell culture.
Type:
Grant
Filed:
April 23, 2021
Date of Patent:
March 8, 2022
Assignee:
Inscripta, Inc.
Inventors:
Phillip Belgrader, Christian Siltanen, William Watterson, Burak Dura, Bruce Chabansky, David Stumbo, Eric Smith, Jorge Bernate
Abstract: The present disclosure provides engineered nucleic acid-guided nickases and optimized scaffolds for making rational, direct edits to nucleic acids in live cells.
Abstract: The present disclosure provides automated modules and instruments for improved detection of nuclease genome editing of live cells. The disclosure provides improved modules—including high throughput modules—for screening cells that have been subjected to editing and identifying and selecting cells that have been properly edited.
Type:
Grant
Filed:
August 13, 2021
Date of Patent:
March 8, 2022
Assignee:
Inscripta, Inc.
Inventors:
Andrew Garst, Michael Graige, Richard Fox, Eileen Spindler, Amy Hiddessen, Phillip Belgrader, Don Masquelier, Bruce Chabansky
Abstract: The present disclosure provides automated multi-module instrumentation and automated methods for performing recursive editing of live cells with curing of editing vectors from prior rounds of editing.
Type:
Grant
Filed:
June 21, 2021
Date of Patent:
February 22, 2022
Assignee:
Inscripta, Inc.
Inventors:
Tian Tian, Charles Johnson, Eileen Spindler
Abstract: The present disclosure provides shuttle vectors for editing exogenous polynucleotides in heterologous live cells, as well as automated methods, modules, and multi-module cell editing instruments and systems for performing the editing methods.
Abstract: The present disclosure provides a sphere-packing lattice electroporation device configured for use as a stand-alone unit or in an automated multi-module cell processing environment and configured to decrease cell processing time and increase cell survival. The sphere-packing lattice utilizes lattice-forming beads that are uniform in size and that self-assemble into a crystalline-like lattice.